Andrea Lobo,  —

Nitrase Therapeutics showed suppressing the activity of an enzyme called synuclein nitrase reduces toxic clumps of the alpha-synuclein protein and normalizes the electrical activity of dopamine-producing, or dopaminergic, neurons derived from Parkinson’s patients. The accumulation of toxic alpha-synuclein clumps is the underlying cause of the progressive death of…

Being exposed to insecticides impacts gastrointestinal function and might increase the risk of developing Parkinson’s disease, a new study in mice shows. The research also shows exposure to a specific insecticide disrupts dopaminergic brain circuitries, and leads to motor deficits associated with Parkinson’s. When it comes to neurological disorders,…

The U.S. Food and Drug Administration (FDA) will review Amneal Pharmaceuticals’ application for IPX203, its extended-release carbidopa/levodopa (CD/LD) tablet for Parkinson’s disease. Results from the Phase 3 RISE-PD clinical trial (NCT03670953) showed IPX203 can control Parkinson’s symptoms safely and effectively for longer periods with less frequent dosing,…

MindMaze is partnering with Mount Sinai Health System in New York to accelerate the access of people with neurological diseases to a pioneer digital neurotherapeutic program to improve patients’ motor and cognitive functions. The program aims to provide high-dose and high-intensity training to improve the brain’s ability…

Aggression aimed at caregivers in Parkinson’s disease and related disorders is associated with patients’ grief in coping with disease progression and related losses, a new study suggests. Fluctuations in cognition also play a role, researchers say. But these behavioral disturbances have serious consequences for caregivers, according to investigators, who…

Treatment with DopaFuse, a continuous oral levodopa-carbidopa delivery system being developed by SynAgile, was safe and lessened motor complications in people with Parkinson’s disease, according to results from a Phase 2 clinical trial. “These results suggest that the DopaFuse [levodopa-carbidopa] delivery system can provide a safe, non-invasive…

Dental care often is irregular in people with Parkinson’s disease, who also require more dental treatments that those without this disease, a study from Denmark reported. High-quality initiatives addressing basic care, from daily oral cleanings to regular checkups that could reduce cavities and tooth extractions, are needed for better…

People who had COVID-19 might have an increased risk for developing neurodegenerative diseases, such as Parkinson’s disease, researchers in Australia found. Moreover, the researchers have offered a possible treatment to reduce the  COVID-induced neuroinflammation. COVID-19 activates an inflammatory response in the brain that is similar to Parkinson’s disease, contributing…

Neural implants combining artificial intelligence with microelectronics could directly modulate the brain’s activity to help treat brain disorders, including Parkinson’s disease. “Neurons talk to each other in part via electrical signals, and a therapeutic neural implant produces electrical stimulation – like a pacemaker for the brain. In cases of…

New York University Langone Health is collaborating with the Michael J. Fox Foundation for Parkinson’s Research in the Parkinson’s Progression Markers Initiative, a research program aiming to contribute to disease diagnosis and treatment. Launched in 2010 by the Michael J. Fox Foundation and a group of academic researchers…